Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
View Patent ↗The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
1. A composition comprising an expression vector comprising a first polynucleotides encoding an optimized Feline Leukemia Virus (FeLV) envelope (ENV) polypeptide and a second polynucleotide encoding an FeLV GAG/PRO polypeptide, wherein the optimized FeLV ENV polypeptide comprises a mutation at amino acid position 527 or equivalent corresponding amino acid position of an FeLV ENV protein, and wherein the mutation comprises a substitution of arginine (R), aspartic acid (D), or methionine (M) for glutamic acid (E), and wherein the polynucleotide encodes an optimized FeLV ENV polypeptide having at least 99% sequence identity to the sequence as set forth in SEQ ID NO: 4.
2. The composition of claim 1 , wherein the first polynucleotide encodes an optimized FeLV ENV polypeptide having the amino acid sequence as set forth in SEQ ID NO: 4, and wherein the second polynucleotide encodes an FeLV GAG/PRO polypeptide having an amino acid sequence as set forth in SEQ ID NO:12.
3. The composition of claim 1 , wherein the polynucleotide encoding the optimized FeLV ENV polypeptide has at least 99% sequence identity to the sequence as set forth in SEQ ID NO: 3, and the polynucleotide encoding FeLV GAG/PRO polypeptide has the sequence as set forth in SEQ ID NO: 10 or 11.
4. An expression vector comprising a first polynucleotide encoding an optimized FeLV ENV polypeptide and a second polynucleotide encoding an FeLV GAG/PRO polypeptide, wherein the optimized FeLV ENV polypeptide comprises a mutation at amino acid position 527, and wherein the mutation comprises a substitution of arginine (R), aspartic acid (D), or methionine (M) for glutamic acid (E), and wherein the first polynucleotide encodes an optimized FeLV ENV polypeptide having at least 99% sequence identity to the sequence as set forth in SEQ ID NO: 4, and wherein the second polynucleotide encodes an FeLV GAG/PRO polypeptide having at least 99% sequence identity to the sequence as set forth in SEQ ID NO:12.
5. The expression vector of claim 4 , wherein the first polynucleotide encodes an optimized FeLV ENV polypeptide having the amino acid sequence as set forth in SEQ ID NO: 4, and wherein the second polynucleotide encodes an FeLV GAG/PRO polypeptide having the amino acid sequence as set forth in SEQ ID NO:12.
6. The expression vector of claim 4 , wherein the polynucleotide encoding the optimized FeLV ENV polypeptide has at least 99% sequence identity to the sequence as set forth in SEQ ID NO:3, and the polynucleotide encoding FeLV GAG/PRO polypeptide has the sequence as set forth in SEQ ID NO: 10 or 11.
7. A method of vaccinating an animal comprising at least one administration of the composition or expression vector of claim 1 or 4 .
8. The method of claim 7 , wherein the method comprises a prime-boost administration regime.
9. The method of claim 7 , wherein the composition is administered at a dosage range from about 10 5 pfu to about 10 9 pfu.
10. The composition of claim 1 , wherein the polynucleotide encodes an optimized FeLV ENV polypeptide having the sequence as set forth in SEQ ID NO: 4.
11. The composition of claim 1 , wherein the second polynucleotide encodes an FeLV GAG/PRO polypeptide having the sequence as set forth in SEQ ID NO:12.
12. The composition of claim 1 , wherein the polynucleotide encoding the optimized FeLV ENV polypeptide has the sequence as set forth in SEQ ID NO: 3, and the polynucleotide encoding FeLV GAG/PRO polypeptide has the sequence as set forth in SEQ ID NO: 10 or 11.
13. The composition of claim 1 , wherein the expression vector is an avipox vector.
14. The expression vector of claim 4 , wherein the expression vector is an avipox vector.
15. The method of claim 8 , wherein the composition is administered at a dosage range from about 10 5 pfu to about 10 9 pfu.